Zyrtec OTC Launch Does Not Deliver Knockout To Rx Remedies – Report
This article was originally published in The Tan Sheet
Executive Summary
Fewer consumers than expected have switched from Rx products to OTC Zyrtec in part because managed care organizations are not discouraging use of prescription allergy medications, according to research by Nielsen and Wolters Kluwer Health
You may also be interested in...
Prepaid Cards Could Help OTC Switches Gain Against Rx Competitors
Medagate Corp.’s payment technology that simplifies insurance reimbursement for OTCs could help level the playing field with competing prescription products.
Zyrtec Model Shows Managed Care’s “Softer” Side For Switching Patients
Sales of Johnson & Johnson's allergy drug Zyrtec show managed care organizations learned from previous switches and used a "softer" approach to steer clients away from Rx drugs to an OTC product, according to market analysts
J&J Ready To Capitalize On Zyrtec OTC Launch As Allergy Drug Hits Shelves
Johnson & Johnson's consumer product business is positioned to capitalize on the launch of nonprescription Zyrtec (cetirizine HCl) allergy medicine, J&J CEO Bill Weldon said during the firm's year-end analyst meeting Jan. 22